Earnings Feed
Start Free
ASCENTAGE PHARMA GROUP INTERNATIONAL·4

May 22, 4:44 PM ET

Zhai Yifan 4

4 · ASCENTAGE PHARMA GROUP INTERNATIONAL · Filed May 22, 2026

Research Summary

AI-generated summary of this filing

Updated

Ascentage Pharma (AAPG) CMO Zhai Converts RSUs, Sells 188,321 Shares

What Happened
CMO Yifan Zhai was the recipient of a large series of derivative awards (RSUs) granted 05/20/2026 that, per the filing, vested/converted on 05/21/2026. The Form 4 shows 1,421,426 RSUs granted on 05/20/2026 (all reported as derivative awards, $0 exercise price in filing). On 05/21/2026 two conversions/exercises of derivative interests for 92,746 and 95,575 shares were reported as acquired and then disposed the same day — a total of 188,321 shares converted and sold. The filing reports $0 consideration for the derivative transactions (the form shows no cash paid for conversion/award).

Key Details

  • Transaction types: A = Award/Grant (RSUs) on 05/20/2026; M = Exercise/Conversion of derivative (conversion of RSUs to shares) on 05/21/2026; M entries for 92,746 and 95,575 shares were acquired and then disposed the same day.
  • Total RSUs granted (05/20/2026): 1,421,426 RSUs (each RSU = contingent right to one ordinary share).
  • Shares converted and sold (05/21/2026): 92,746 + 95,575 = 188,321 shares.
  • Reported consideration: $0 shown for the derivative awards/conversions in the filing (exercise/award entries list $0). The Form 4 does not show market sale proceeds in these derivative lines.
  • Ownership after transaction: Not specified in the summary data provided here — see the official Form 4 for the “amount of securities beneficially owned” after the transactions.
  • Notable footnotes: several footnotes indicate some securities are held by the reporting person’s spouse or related trusts/entities (Dajun Yang Dynasty Trust, spouse holdings, HealthQuest Pharma Limited) and the reporting person disclaims beneficial ownership except to the extent of pecuniary interest (F1–F3). Footnotes F8–F10 state certain RSUs vested in full on 05/21/2026 (some grants were to the reporting person and some to the spouse). Vesting schedules and option terms for other awards are described in F4–F7.
  • Timeliness: Filing was dated 05/22/2026 for transactions on 05/20–05/21/2026 — the filing appears to be timely under Section 16 (filed the next business day).

Context
A = award/grant entries are RSUs (a right to receive shares upon vesting); M = conversion/exercise of those derivative rights into actual shares. Here the bulk action was awards/vesting (not an open-market purchase). The conversion followed by same-day dispositions is common when shares are sold after vesting (for tax withholding or liquidity), but the Form 4 itself does not state the reason. For retail investors: awards/vesting increase insider exposure to company equity but do not necessarily signal a new purchase conviction the way an open-market buy would. See the full Form 4 for granular footnote mappings and any reported proceeds or withholding transactions.

Insider Transaction Report

Form 4
Period: 2026-05-20
ASCENTAGE PHARMA GROUP INTERNATIONALAAPG
Zhai Yifan
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2026-05-21+92,746→ 405,280 total
  • Exercise/Conversion

    Ordinary Shares

    [F2]
    2026-05-21+95,575→ 1,193,569 total(indirect: See Footnote (2))
  • Award

    Restricted stock units

    [F4]
    2026-05-20+103,365→ 103,365 total
    Exercise: $0.00→ Ordinary Shares (103,365 underlying)
  • Award

    Restricted stock units

    [F5]
    2026-05-20+214,999→ 214,999 total
    Exercise: $0.00→ Ordinary Shares (214,999 underlying)
  • Award

    Options

    [F6]
    2026-05-20+214,988→ 214,988 total
    Exercise: $6.58→ Ordinary Shares (214,988 underlying)
  • Award

    Options

    [F7]
    2026-05-20+103,364→ 103,364 total
    Exercise: $8.12→ Ordinary Shares (103,364 underlying)
  • Award

    Restricted stock units

    [F8]
    2026-05-20+92,746→ 92,746 total
    Exercise: $0.00From: 2026-05-21→ Ordinary Shares (92,746 underlying)
  • Exercise/Conversion

    Restricted stock units

    [F9]
    2026-05-21−92,746→ 0 total
    Exercise: $0.00→ Ordinary Shares (92,746 underlying)
  • Award

    Restricted stock units

    [F8]
    2026-05-20+95,575→ 95,575 total(indirect: By Spouse)
    Exercise: $0.00From: 2026-05-21→ Ordinary Shares (95,575 underlying)
  • Exercise/Conversion

    Restricted stock units

    [F10]
    2026-05-21−95,575→ 0 total(indirect: By Spouse)
    Exercise: $0.00→ Ordinary Shares (95,575 underlying)
  • Award

    Restricted stock units

    [F5]
    2026-05-20+298,195→ 298,195 total(indirect: By Spouse)
    Exercise: $0.00→ Ordinary Shares (298,195 underlying)
  • Award

    Options

    [F6]
    2026-05-20+298,194→ 298,194 total(indirect: By Spouse)
    Exercise: $6.58→ Ordinary Shares (298,194 underlying)
Holdings

  • Ordinary Shares

    [F1]
    (indirect: See Footnote (1))
    22,054,131

  • Ordinary Shares

    [F3]
    (indirect: See Footnote (3))
    14,089,111
Footnotes (10)
  • [F1]Shares held by Dajun Yang Dynasty Trust, of which the Reporting Person's spouse is the investment advisor. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
  • [F10]Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person's spouse on 05/20/2026.
  • [F2]Shares held by Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
  • [F3]Shares held by HealthQuest Pharma Limited, an entity controlled by the Reporting Person. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
  • [F4]Each restricted stock unit (the "RSUs") represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and have no expiration date.
  • [F5]The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date.
  • [F6]The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant.
  • [F7]The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and expire ten years from the date of grant.
  • [F8]The RSUs vested on 05/21/2026 and had no expiration date.
  • [F9]Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person on 05/20/2026.
Signature
/S/Thomas J. Knapp, Attorney-in-Fact|2026-05-22

Documents

2 files
  • 4
    marketforms-73254.xmlPrimary

    PRIMARY DOCUMENT

  • EX-24
    poa.htm

    POA DOCUMENT